Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
Opinion|Podcasts|August 1, 2024
Optimizing Treatment Outcomes in Retinal Vein Occlusion
Listen
0:00 / 0:00
Key Takeaways
- Retinal vein occlusion requires strategic treatment selection and diagnostic approaches to address its complex challenges effectively.
- Angiopoietin-2 significantly impacts RVO progression and treatment outcomes, necessitating its consideration in management strategies.
A panel of ophthalmologists discuss strategies for improving patient outcomes in retinal vein occlusion with anti-VEGF and other therapies.
Advertisement
0:50 RVO Challenges
2:30 Treatment Selection
8:00 Diagnostics
10:50 Role of Ang-2 in RVO
13:50 Steroids in RVO
18:00 Patient Education
Advertisement
Related to this article
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
Finerenone Outperforms Spironolactone, Eplerenone in HFpEF, HFmrEF Renal Outcomes
2
Hidradenitis Suppurativa Care: Expectations, Comorbidities, and Wound Care
3
Fall Clinical 2026 First Half Recap: Psoriasis, Atopic Dermatitis, and More
4
Why Early Advanced Therapy Matters in Hidradenitis Suppurativa
5